Results 101 to 110 of about 37,793 (186)

Structural analysis of the flexibility of the Ubl2 domain within the papain‐like protease of SARS‐CoV‐2

Acta Crystallographica Section F, Volume 82, Issue 6, Page 222-230, June 2026.
The ubiquitin‐like domain 2 (Ubl2) of the SARS‐CoV‐2 virus is necessary for the stability and catalytic efficiency of its papain‐like protease (PLpro). Our crystallographic study reveals that the Ubl2 domain exhibits notable flexibility and can adopt a conformation that places itself away from the PLpro catalytic domain, representing a new conformation
Gian Luca Freiherr von Scholley, Martina Schaefer, Mark D. Tully, Marc-Andre Hograindleur, Montserrat Soler-López, Roman C. Hillig, Christoph Mueller-Dieckmann, Eaazhisai Kandiah   +7 more
wiley   +1 more source

Toward Secure Supply of Remdesivir via a 2-Pot Triazine Synthesis: Supply Centered Synthesis

, 2020
Pyrrolotriazine 1 is an important precursor to Remdesivir, and an efficient synthesis is disclosed. This route features atom economy and reduced derivatization of starting materials, by making use of highly abundant, commoditized raw material inputs ...
Flavio S. P., Cardoso, Rodger W., Stringham, Joshua D., Sieber, Dinesh J., Paymode, Daniel W., Cook, B. Frank, Gupton, Justina, Burns, David, Snead, John W., Tomlin, Toolika, Agrawal   +9 more
core   +1 more source

Systematic reviews of remdesivir for COVID-19

, 2022
Project assessing coverage, completeness and replication & duplication of systematic reviews of remdesivir for COVID ...
Steve McDonald
core   +2 more sources

Development and implementation of a computerised clinical decision support system for hospital‐in‐the‐home patient identification

Internal Medicine Journal, Volume 56, Issue 6, Page 991-1001, June 2026.
ABSTRACT Background Identification of appropriate patients for hospital‐in‐the‐home (HITH) remains a significant challenge. We hypothesise that a human‐centred design (HCD) approach can assist in developing a computerised clinical decision support system (CDSS) to address this issue via leveraging data within the electronic medical record (EMR).
Seok Ming Lim, Thomas Kitt‐Thompson, Douglas Forsyth Johnson, Michael Turner, Adam Boulton, Samantha Plumb, Daniel Capurro, Wen‐Kwang Lim   +7 more
wiley   +1 more source

ADME and Pharmacokinetic Properties of Remdesivir: Its Drug Interaction Potential

, 2021
On 11 March 2020, the World Health Organization (WHO) classified the Coronavirus Disease 2019 (COVID-19) as a global pandemic, which tested healthcare systems, administrations, and treatment ingenuity across the world.
Hopefl, Robert, Deb, Subrata, Anthony Allen Reeves, Reeves, Anthony Allen, Subrata Deb, Rebecca Bejusca, Robert Hopefl, Bejusca, Rebecca   +7 more
core   +1 more source

Remdesivir triphosphate as a substrate of human PrimPol

, 2023
Trabajo presentado en el 6th DNA Polymerases meeting, celebrado en Stockholm (Suecia) del 22 al 25 de mayo de 2022.Remdesivir is a broad-spectrum antiviral drug which has been recently approved for its emergency use to treat COVID-19.
Jiménez-Juliana, Marcos, Martínez-Jiménez, María I., Blanco Dávila, Luis   +2 more
core  

Characterization of Drug–Drug Interactions for Remdesivir, an Intravenous Antiviral for SARS‐CoV‐2, in Healthy Participants

Clinical and Translational Science
Remdesivir is an intravenous antiviral approved worldwide for the treatment of COVID‐19 in adults and children. Remdesivir, as a prodrug inhibitor of RNA polymerase, undergoes intracellular activation to form the active metabolite along with 2 inactive ...
Jack Chang, Aryun Kim, Rita Humeniuk, Naveed A. Shaik, Helen Winter, Chi‐Chi Peng, Deqing Xiao, Mazin Abdelghany, Joe Llewellyn, Santosh Davies, Kandace Golden, Shuguang Chen, Robert H. Hyland, Luzelena Caro   +13 more
doaj   +1 more source

Percentage of laboratory values imputed by dexamethasone receipt for remdesivir and non-remdesivir groups.

For the group of patients not receiving remdesivir, the percentage of each laboratory value which was imputed, by control group (A) and treatment (B).
Justin F. Rousseau (18196027), Richard Zhou (9524030), Kaitlyn E. Johnson (7134950), Paul J. Rathouz (13208130)   +3 more
core   +1 more source

Anatomy of a molecule: What makes remdesivir unique?

, 2020
Clinical trials around the world are testing remdesivir, a nucleotide analog, for possible effects against the novel coronavirus. We asked some experts what makes the molecule interesting.https://www.asbmb.org/asbmb-today/science/031720/what-makes ...
Seley-Radtke, Katherine, Oldach, Laurel
core   +1 more source

Assessing the effect of remdesivir alone and in combination with corticosteroids on time to death in COVID-19: A propensity score-matched analysis

Journal of Clinical Virology Plus
Background: This study aimed to evaluate the impact of remdesivir, alone or in combination with corticosteroids, on the time to death in COVID-19 patients. Methods: This retrospective cohort study was conducted between March 20, 2020, and March 18, 2021,
Mohamad Amin Pourhoseingholi, Mehdi Azizmohammad Looha, Saba Ilkhani, Hamidreza Hatamabadi, Amir Sadeghi, Seyed Amir Ahmad Safavi-Naini, Kamran Heidari, Nazanin Taraghikhah, Mohammad Mahdi Fallah, Reyhaneh Kalantar, Nariman Naderi, Romina Esbati, Nastaran Ebrahimi, Ali Solhpour, Tannaz Jamialahmadi, Amirhossein Sahebkar   +15 more
doaj   +1 more source